MedTech
Precision decision infrastructure for medical technology and device intelligence.
Medical technology companies face a compounding accuracy crisis: AI systems that generate plausible but unverifiable clinical recommendations expose organizations to regulatory action, patient safety incidents, and catastrophic liability. Traditional AI cannot distinguish between corroborated medical evidence and probabilistic inference.
The instrument enforces evidence governance at every stage. Clinical claims are classified against source literature before reaching any decision surface. Device performance data flows through parallel reasoning branches that prevent single-point analytical failures. Every output carries a cryptographic receipt linking it to its evidentiary basis.
Industry Context
The global medical device market exceeds $500B annually, with regulatory scrutiny intensifying across every major jurisdiction. The EU Medical Device Regulation (MDR) has fundamentally changed the evidentiary requirements for device approval and post-market surveillance. Simultaneously, the FDA is increasing its focus on real-world evidence and AI-driven analytical tools used in regulatory submissions. Organizations that cannot demonstrate auditable, evidence-governed reasoning in their analytical processes face mounting regulatory risk and competitive disadvantage.
Capability Configuration
Structured aggregation of clinical trial data, real-world evidence, and device performance metrics across multiple therapeutic areas. The system cross-references published literature, adverse event databases, and institutional clinical data to produce evidence-weighted conclusions that distinguish between established clinical fact and statistical inference.
Evidence-governed generation of 510(k) substantial equivalence summaries, MDR technical documentation, and post-market surveillance reports. Every claim in the generated documentation is traced to its source evidence and classified by evidence strength, enabling regulatory reviewers to verify the analytical basis of each conclusion.
Continuous analytical monitoring of device telemetry with anomaly detection, trend analysis, and root cause identification. The system processes field performance data through parallel reasoning branches to distinguish between normal variation, emerging failure patterns, and statistically significant performance degradation.
Multi-branch risk assessment for device classification, biocompatibility evaluation, and clinical equivalence determination. Each risk dimension is evaluated independently before synthesis, preventing the common analytical failure where a favorable assessment in one dimension masks unfavorable evidence in another.
Systematic monitoring and analysis of adverse event reports, complaint data, and field performance metrics to identify safety signals before they reach regulatory reporting thresholds. Parallel branches independently assess signal strength, clinical significance, and reporting obligations.
Multi-scenario analysis of clinical trial design, endpoint selection, and statistical powering. The system models alternative trial designs in parallel to identify the approach most likely to demonstrate clinical benefit while maintaining regulatory acceptance.
How the Framework Could Be Applied
Hypothetical: Cardiac Device Signal Detection
Hypothetical: Clinical Trial Evidence Synthesis
Decision Surfaces
Deployment Phases
Map regulatory workflows, clinical data sources, evidence requirements, and existing analytical processes
Connect clinical databases, device registries, adverse event systems, and literature sources to the Evidence Kernel
Tune sector module for medical device classification hierarchies, regulatory language patterns, and clinical evidence standards
Parallel run against historical submissions and surveillance reports for accuracy verification and gap identification
Full deployment with monitoring, governance reporting, and clinical review integration
Related Deployment Contexts
Framework Application
How the instrument's core architectural components are configured for this sector's specific decision requirements.
Parallel reasoning across clinical evidence dimensions
Deploys minimum three branches per clinical assessment: primary evidence review, contradictory evidence search, and alternative interpretation analysis. Prevents the common failure where favorable evidence in one therapeutic area masks unfavorable signals in adjacent indications.
Clinical data repository with provenance tracking
Ingests and indexes clinical trial databases, adverse event registries, published literature, and institutional device performance data. Every data element carries source metadata including publication date, study design, sample size, and evidence grade.
Contradiction detection across clinical data sources
Identifies cases where clinical trial results, real-world evidence, and device performance data reach different conclusions about the same clinical question. Surfaces these contradictions for clinical review rather than averaging or suppressing them.
Regulatory compliance overlay management
Maintains current regulatory requirements across FDA, EU MDR, Health Canada, TGA, and PMDA jurisdictions. Automatically flags when evidence requirements change due to regulatory guidance updates.
Quality gating for clinical conclusions
Enforces evidence sufficiency thresholds calibrated to the clinical risk class of the device under analysis. Higher-risk devices require stronger evidence classification before conclusions are released.
Scenario breadth for risk assessment
Ensures that device risk assessments consider sufficient failure modes, use environments, and patient populations. Prevents narrow risk analysis that misses edge-case scenarios.
Decision Classes
The categories of decisions this sector deployment addresses, their frequency, and the stakes involved.
Regulatory Submission Decisions
Determining predicate device selection, substantial equivalence arguments, and clinical evidence sufficiency for 510(k), PMA, and MDR submissions.
Submission rejection, market access delay, competitive disadvantage
Post-Market Safety Decisions
Evaluating adverse event signals, determining reporting obligations, and assessing whether field performance data indicates a safety concern requiring corrective action.
Patient safety, regulatory enforcement, product recall
Clinical Evidence Decisions
Assessing the strength and sufficiency of clinical evidence for device claims, including real-world evidence integration and literature synthesis.
Regulatory credibility, clinical adoption, reimbursement
Design and Development Decisions
Evaluating design inputs against clinical requirements, risk analysis outputs, and regulatory expectations during the product development lifecycle.
Development cost, time-to-market, design control compliance
Governance Requirements
Standards and regulatory frameworks the instrument is configured to support in this deployment context.
FDA 21 CFR Part 820
Quality System Regulation requiring documented design controls, risk management, and corrective action processes for medical devices.
Full alignment with design control documentation, CAPA analysis, and complaint handling workflows
EU MDR 2017/745
Medical Device Regulation requiring clinical evaluation, post-market surveillance, and technical documentation for CE marking.
Structured output formats aligned with MDR Annex II and Annex XIV requirements
ISO 14971
Risk management standard for medical devices covering hazard identification, risk estimation, and risk control.
Multi-branch risk analysis with evidence-traced hazard identification and residual risk assessment
ISO 13485
Quality management system standard specific to medical device organizations.
Audit trail documentation compatible with QMS record-keeping requirements
Configure for MedTech
Begin with an architecture review to map your decision environment, identify integration points, and configure the instrument for your operational requirements.